Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

UBS maintains neutral rating on Sanofi with €100 target price

EditorRachael Rajan
Published 08/12/2023, 17:56
© Reuters.
SASY
-

PARIS - UBS has maintained its neutral stance on the pharmaceutical company Sanofi (NASDAQ:SNY), setting a target price of €100. This valuation reflects the company's confidence in its drug Dupixent and its successors, which were a focal point during their recent investor day.

Sanofi has projected that its new pharmaceutical products, coupled with an expanding vaccine portfolio and the sustained performance of Dupixent, will collectively generate over €10 billion in annual sales by 2030.

The healthcare giant's outlook is buoyed by the potential of its current star treatment, Dupixent, which is anticipated to continue its successful run. The investor day presentations highlighted the drug's capacity to be substituted in the future, which could play a critical role in Sanofi's growth strategy.

Sanofi's ambitious forecast for its pharmaceutical lineup underscores the company's strategic focus on innovation and market expansion. The €10 billion revenue target by 2030 is expected to be driven by a combination of new drug introductions and vaccine developments alongside Dupixent's ongoing success.

Investors and market watchers are keeping a close eye on Sanofi's progress as it aims to achieve these bold financial milestones in the coming years. UBS's current price goal suggests a 16% upside, indicating cautious optimism about the company's ability to meet its targets amidst a competitive pharmaceutical landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.